News

Adcentrx Therapeutics, a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, announced that…
Read More...

Opus Genetics, Inc. a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders,…
Read More...

BioVaxys Technology Corp. and Sona Nanotech Inc. have announced a research collaboration to develop innovative cancer therapeutics by combining BioVaxys' DPX immune-educating platform…
Read More...

Novo Nordisk has announced that the FDA has accepted the New Drug Application (NDA) for a once-daily 25 mg oral formulation of Wegovy (semaglutide) for chronic weight management in…
Read More...

TAE Life Sciences and The Ohio State University Comprehensive Cancer Center have announced a landmark collaboration focused on advancing boron-based drug innovation for Boron Neutron…
Read More...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI™…
Read More...

VERAXA Biotech AG, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp., announced a co-discovery alliance with…
Read More...

Illumina and Ovation.io have announced a groundbreaking collaboration to create the largest commercially available clinical multiomic dataset from 25,000 patients treated with GLP-1…
Read More...

Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu), a novel human monoclonal antibody that blocks the neonatal…
Read More...

Creyon Bio, Inc. announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, development and commercialization of…
Read More...

QIAGEN announced the expansion of its cell and gene therapy (CGT) portfolio with enhanced digital PCR (dPCR) solutions tailored for lentivirus-based applications. These solutions are…
Read More...

AbbVie announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This…
Read More...

Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience are joining forces to provide insights into the day-to-day experiences of people living with psychiatric…
Read More...

Abeona Therapeutics Inc. announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN (pronounced as ‘ZEE-vah-skin’) (prademagene zamikeracel) gene-modified cellular…
Read More...

Merck, known as MSD outside the U.S. and Canada, has announced the start of construction on a $1 billion, 470,000-square-foot Biologics Center of Excellence in Wilmington, Delaware.…
Read More...

Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease…
Read More...

Biohaven Ltd. (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to…
Read More...

Debiopharm Research & Manufacturing S.A., a Swiss-based global biopharmaceutical company aiming to cure cancer and infectious diseases, and Oncodesign Services, a leading CRO…
Read More...

Repertoire Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, announced that it has entered into a…
Read More...

Granite Bio AG, a clinical-stage immunology company, has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant…
Read More...